Skip to main content

Gene Therapy Offers Hope for a Cure

\

Scientists are working to develop a gene therapy that may offer a cure for thalassemia. Such a treatment might involve inserting a normal beta globin gene (the gene that is abnormal in this disease) into the patient's stem cells, the immature bone marrow cells that are the precursors of all other cells in the blood.

Another form of gene therapy could involve using drugs or other methods to reactivate the patient's genes that produce fetal hemoglobin - the form of hemoglobin found in fetuses and newborns. Scientists hope that spurring production of fetal hemoglobin will compensate for the patient's deficiency of adult hemoglobin.

Labels:

Comments

Post a Comment

Popular posts from this blog

Can Thalassemias Be Prevented?

Thalassemias can't be prevented because they're inherited (passed on from parents to children). However, these bleeding disorders can be found before birth through prenatal tests. Family genetic studies may help find out whether people have missing or altered hemoglobin genes that cause thalassemias. (For more information, see "How Are Thalassemias Diagnosed?") If you know of family members who have thalassemias and you're thinking of having children, consider talking with your doctor and/or a genetic counselor. They can help determine your risk for passing on the disorder to your child.
Post a Comment
Read more

What do we know about heredity and thalassemia

Thalassemia is a group of inherited or genetic diseases that affect the body's ability to produce hemoglobin, usually resulting in anemia. Hemoglobin, a protein found in red blood cells, is necessary for carrying oxygen throughout the body. Thalassemia is passed to children by parents who carry the gene for the disease. There are many different types of thalassemia, ranging from mild to life-threatening or fatal without blood transfusions and appropriate treatment. Thalassemia trait, also known as Mediterranean anemia, is one of the most common genetic disorders. Rarely resulting in illness, it affects hundreds of millions of people around the world. Each year about 100,000 babies are born with severe forms of thalassemia. The disease occurs most often in people of Italian, Greek, Middle Eastern, South and Southeast Asian, and African ancestry. The type and severity of the illness is determined by the specific genetic abnormality present. Today, better understanding of the ca...
Post a Comment
Read more

Innovations and Research

As one of five thalassemia centers in the United States designated by the National Institutes of Health, the Children's Hospital Boston thalassemia program provides patients with access to experts in the field and the most cutting-edge clinical trials available in the world. One promising recent study, now awaiting approval by the FDA, tested the effectiveness of a new oral iron chelator, deferisirox. Researchers from Children's Hospital Boston have been at the forefront of thalassemia research and treatment for decades. Important advances in the field that were made here include: • Recognition of the important role of hypertransfusion by Dr. David Nathan, Senior Associate in Hematology, in the 1960s. • Demonstration of effective iron chelation by subcutaneous pump deferoxamine (Desferal ®) by Dr. Richard Proper and David Nathan in the 1970s. • Elucidation of the molecular biology of thalassemia syndromes by Drs. Nathan, YW Kan, Stuart Orkin and others.
Post a Comment
Read more